

Aref Al-Kali

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2789503/publications.pdf>

Version: 2024-02-01

219
papers

3,020
citations

201385

27
h-index

214527

47
g-index

220
all docs

220
docs citations

220
times ranked

3955
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. <i>Leukemia and Lymphoma</i> , 2022, 63, 199-204.	0.6	3
2	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. <i>British Journal of Haematology</i> , 2022, 196, 975-983.	1.2	14
3	Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. <i>American Journal of Hematology</i> , 2022, 97, E62.	2.0	17
4	Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. <i>Blood Cancer Journal</i> , 2022, 12, 12.	2.8	1
5	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response. <i>Blood Cancer Journal</i> , 2022, 12, 7.	2.8	5
6	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (<sc>MDSâ€RS</sc>) but not in <sc>MDS</sc>/<sc>MPNâ€RSâ€T</sc>. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	6
7	Gilteritinib clinical activity in relapsed/refractory <sc><i>FLT3</i></sc> mutated <sc>acute myeloid leukemia</sc> previously treated with <sc><i>FLT3</i></sc> inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 322-328.	2.0	21
8	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. <i>Blood Cancer Journal</i> , 2022, 12, 26.	2.8	5
9	<i>SF3B1</i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. <i>Haematologica</i> , 2022, 107, 1189-1192.	1.7	3
10	Erythrocytosis associated with <i>EPAS1</i>, (<i>HIF2A</i>), <i>EGLN1</i>, (<i>PHD2</i>), <i>VHL</i>, <i>EPOR</i> or <i>BPGM</i> mutations: The Mayo Clinic experience. <i>Haematologica</i> , 2022, 107, 1201-1204.	1.7	4
11	Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. <i>American Journal of Hematology</i> , 2022, 97, 630-637.	2.0	11
12	Isolated anemia in patients with large granular lymphocytic leukemia (LGLL). <i>Blood Cancer Journal</i> , 2022, 12, 30.	2.8	4
13	DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation. <i>Frontiers in Oncology</i> , 2022, 12, 849376.	1.3	9
14	Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2022, 36, 1693-1696.	3.3	1
15	Realâ€world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	10
16	Realâ€world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	13
17	Deep neural network for cell type differentiation in myelodysplastic syndrome diagnosis performs similarly when trained on compensated or uncompensated data. , 2022, , .		1
18	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with â€œ7+3â€œ. <i>Blood Cancer Journal</i> , 2022, 12, 55.	2.8	4

#	ARTICLE	IF	CITATIONS
19	Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms. American Journal of Hematology, 2022, 97, 1013-1022.	2.0	7
20	Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy. American Journal of Ophthalmology Case Reports, 2022, 26, 101554.	0.4	3
21	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20mg twice daily or higher: A real-world experience. British Journal of Haematology, 2022, 198, .	1.2	7
22	Characteristics and prognosis of mutated <i>STAG2</i> myeloid neoplasms.. Journal of Clinical Oncology, 2022, 40, e19014-e19014.	0.8	0
23	Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs. Blood Cancer Journal, 2022, 12, .	2.8	1
24	Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.. Journal of Clinical Oncology, 2022, 40, TPS7080-TPS7080.	0.8	0
25	Characteristics and prognosis of <i>DDX41</i> - and <i>GATA2</i> -mutated myeloid neoplasms.. Journal of Clinical Oncology, 2022, 40, e19010-e19010.	0.8	0
26	Racial disparities in patients with <i>TP53</i> mutated acute myeloid leukemia.. Journal of Clinical Oncology, 2022, 40, e19007-e19007.	0.8	0
27	Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood Cancer Journal, 2022, 12, .	2.8	7
28	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia – A Single Center Retrospective Study. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 1-9.	1.2	8
29	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer Journal, 2021, 11, 49.	2.8	28
30	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus <i>HMA</i> ±venetoclax chemotherapy. American Journal of Hematology, 2021, 96, E108-E111.	2.0	7
31	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer Journal, 2021, 11, 43.	2.8	11
32	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer Journal, 2021, 11, 47.	2.8	7
33	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 46.	2.8	6
34	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Advances, 2021, 5, 2272-2278.	2.5	19
35	Classification of Monocytes, Promonocytes and Monoblasts Using Deep Neural Network Models: An Area of Unmet Need in Diagnostic Hematopathology. Journal of Clinical Medicine, 2021, 10, 2264.	1.0	5
36	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. American Journal of Hematology, 2021, 96, 781-789.	2.0	46

#	ARTICLE	IF	CITATIONS
37	Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations. American Journal of Clinical Pathology, 2021, 156, 679-690.	0.4	10
38	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer Journal, 2021, 11, 122.	2.8	7
39	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 2021, 35, 3542-3550.	3.3	97
40	Pregnancy in patients with myelofibrosis: Mayo's Florence series of 24 pregnancies in 16 women. British Journal of Haematology, 2021, 195, 133-137.	1.2	2
41	Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy. American Journal of Hematology, 2021, 96, E362-E367.	2.0	4
42	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. British Journal of Haematology, 2021, 195, 413-416.	1.2	9
43	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. American Journal of Hematology, 2021, 96, 1450-1460.	2.0	19
44	Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. American Journal of Hematology, 2021, 96, E433-E436.	2.0	10
45	JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy. Blood, 2021, 138, 2886-2889.	0.6	12
46	Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies. Blood, 2021, 138, 3688-3688.	0.6	0
47	Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy. Blood, 2021, 138, 36-36.	0.6	0
48	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. Blood, 2021, 138, 1267-1267.	0.6	0
49	Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 2592-2592.	0.6	0
50	Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. Blood, 2021, 138, 219-219.	0.6	3
51	Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 3684-3684.	0.6	0
52	Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. Blood, 2021, 138, 3657-3657.	0.6	1
53	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). Blood, 2021, 138, 1096-1096.	0.6	0
54	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. Blood, 2021, 138, 3368-3368.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study. <i>Blood</i> , 2021, 138, 2158-2158.	0.6	5
56	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 3691-3691.	0.6	1
57	<i>DDX41</i> Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic <i>DDX41</i>: Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort. <i>Blood</i> , 2021, 138, 3693-3693.	0.6	2
58	Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial. <i>Blood</i> , 2021, 138, 1517-1517.	0.6	1
59	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. <i>Leukemia</i> , 2020, 34, 656-661.	3.3	32
60	Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. <i>Modern Pathology</i> , 2020, 33, 334-343.	2.9	18
61	Clinical utility of fluorescence in situ hybridization-based diagnosis of <i>BCR-ABL1</i> like (<sc>P</sc> hiladelphia chromosome like) <sc>B</sc>-acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, E68-E72.	2.0	4
62	Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. <i>Annals of Hematology</i> , 2020, 99, 2119-2124.	0.8	7
63	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 121.	2.8	21
64	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	2.2	56
65	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. <i>American Journal of Hematology</i> , 2020, 95, 1511-1521.	2.0	83
66	A population-based study of chronic neutrophilic leukemia in the United States. <i>Blood Cancer Journal</i> , 2020, 10, 68.	2.8	8
67	Characteristics of patients with myelodysplastic syndrome with balanced translocations. <i>British Journal of Haematology</i> , 2020, 190, 244-248.	1.2	1
68	Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). <i>British Journal of Haematology</i> , 2020, 189, e104-e108.	1.2	8
69	A population-based study of chronic eosinophilic <sc>leukemia</sc> otherwise specified in the United States. <i>American Journal of Hematology</i> , 2020, 95, E257.	2.0	6
70	Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes. <i>Anticancer Research</i> , 2020, 40, 3883-3888.	0.5	2
71	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. <i>Annals of Hematology</i> , 2020, 99, 513-518.	0.8	1
72	Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after [®]CLAG-M[™] vs. [®]MEC[™]. <i>Leukemia Research</i> , 2020, 49, 106300.	0.4	8

#	ARTICLE	IF	CITATIONS
73	Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the <sc>SARS-CoV-2</sc> pandemic. American Journal of Hematology, 2020, 95, E203-E208.	2.0	10
74	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. Blood, 2020, 136, 39-40.	0.6	1
75	Immune-Related Hematologic Adverse Events in the Context of Checkpoint Inhibitors. Blood, 2020, 136, 31-32.	0.6	1
76	Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood, 2020, 136, 909-913.	0.6	36
77	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Advances, 2020, 4, 5716-5721.	2.5	9
78	Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors. Blood, 2020, 136, 5-7.	0.6	1
79	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. Blood, 2020, 136, 26-27.	0.6	1
80	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. Blood, 2020, 136, 44-44.	0.6	0
81	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. Blood, 2020, 136, 34-35.	0.6	0
82	IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience. Blood, 2020, 136, 43-44.	0.6	0
83	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. Blood, 2020, 136, 35-36.	0.6	0
84	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. Blood, 2020, 136, 30-31.	0.6	0
85	A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses. Leukemia and Lymphoma, 2019, 60, 559-561.	0.6	9
86	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 246-249.	0.6	0
87	Etiologies of Extreme Thrombocytosis: A Contemporary Series. Mayo Clinic Proceedings, 2019, 94, 1542-1550.	1.4	6
88	Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia. Nature Communications, 2019, 10, 5051.	5.8	17
89	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. Mayo Clinic Proceedings, 2019, 94, 1467-1474.	1.4	12
90	Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin. British Journal of Haematology, 2019, 187, e51-e54.	1.2	13

#	ARTICLE	IF	CITATIONS
91	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. <i>Leukemia and Lymphoma</i> , 2019, 60, 2483-2487.	0.6	3
92	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. <i>American Journal of Hematology</i> , 2019, 94, 767-779.	2.0	51
93	<p>An Erythrocytosis-Associated Mutation in the Zinc Finger of PHD2 Provides Insights into Its Binding of p23<p>. <i>Hypoxia (Auckland, N Z)</i> , 2019, Volume 7, 81-86.	1.9	1
94	In replyâ€“Myelodysplastic Syndrome Over Time. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2594.	1.4	0
95	Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. <i>Annals of Hematology</i> , 2019, 98, 331-337.	0.8	5
96	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 990-999.	0.6	9
97	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 4560-4560.	0.6	1
98	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019, 134, 673-673.	0.6	66
99	Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study. <i>Blood</i> , 2019, 134, 115-115.	0.6	19
100	A Phase 1 Study of Lenzilumab, a humanized recombinant Anti-Human Granulocyte-Macrophage Colony-Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019, 134, 4234-4234.	0.6	4
101	Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30). <i>Blood</i> , 2019, 134, 3015-3015.	0.6	1
102	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). <i>Blood</i> , 2019, 134, 4182-4182.	0.6	1
103	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. <i>Blood</i> , 2019, 134, 3005-3005.	0.6	0
104	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). <i>Blood</i> , 2019, 134, 5441-5441.	0.6	0
105	Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias. <i>Blood</i> , 2019, 134, 5406-5406.	0.6	0
106	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. <i>Blood</i> , 2019, 134, 3863-3863.	0.6	1
107	DNA Cytosine-Demethylating Agent 5-Aza-2'-Deoxycytidine Targets Leukemia Cells through Reducing DNA N6-Methyladenine. <i>Blood</i> , 2019, 134, 2513-2513.	0.6	0
108	The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults. <i>Blood</i> , 2019, 134, 4249-4249.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. <i>Blood</i> , 2019, 134, 1710-1710.	0.6	0
110	Pre- ϵ anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E144-E146.	2.0	2
111	Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 2737-2739.	0.6	9
112	HDL-AuNPs-BMS Nanoparticle Conjugates as Molecularly Targeted Therapy for Leukemia. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 14454-14462.	4.0	12
113	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1754-1758.	2.0	6
114	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2018, 8, 18.	2.8	19
115	Momelotinib therapy for myelofibrosis: a 7-year follow-up. <i>Blood Cancer Journal</i> , 2018, 8, 29.	2.8	49
116	Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 229-232.	0.6	2
117	Therapy related ϵ chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from <i>de novo</i> CMML. <i>American Journal of Hematology</i> , 2018, 93, 65-73.	2.0	49
118	A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target. <i>Leukemia</i> , 2018, 32, 865-873.	3.3	44
119	A dynamic N6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. <i>Cell Research</i> , 2018, 28, 1062-1076.	5.7	152
120	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, E398-E401.	2.0	1
121	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and <i>FLT3-ITD</i> mutational status. <i>American Journal of Hematology</i> , 2018, 93, E401-E404.	2.0	3
122	A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome. <i>Systematic Reviews</i> , 2018, 7, 144.	2.5	15
123	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 82.	2.8	24
124	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 923-932.	2.5	114
125	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. <i>American Journal of Hematology</i> , 2018, 93, E355-E357.	2.0	2
126	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. <i>Leukemia Research</i> , 2018, 71, 60-62.	0.4	18

#	ARTICLE	IF	CITATIONS
127	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1363-1374.	1.4	20
128	Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial. <i>Blood</i> , 2018, 132, 437-437.	0.6	4
129	A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results. <i>Blood</i> , 2018, 132, 1443-1443.	0.6	0
130	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. <i>Blood</i> , 2018, 132, 5510-5510.	0.6	0
131	Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 2722-2722.	0.6	2
132	The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia. <i>Blood</i> , 2018, 132, 5440-5440.	0.6	1
133	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2018, 132, 3268-3268.	0.6	0
134	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2018, 132, 4344-4344.	0.6	0
135	Favorable Outcomes of Acute Leukemia of Ambiguous Lineage Treated with Hypercvad: A Multi-Center Retrospective Study. <i>Blood</i> , 2018, 132, 2658-2658.	0.6	0
136	Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC. <i>Blood</i> , 2018, 132, 2678-2678.	0.6	0
137	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. <i>Blood</i> , 2018, 132, 2689-2689.	0.6	0
138	Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2017, 3, 936.	3.4	90
139	The 2016 revised World Health Organization definition of "myelodysplastic syndrome with isolated del(5q)" versus double cytogenetic abnormalities. <i>British Journal of Haematology</i> , 2017, 178, 57-60.	1.2	7
140	Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*. <i>American Journal of Hematology</i> , 2017, 92, 866-871.	2.0	17
141	Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2588-2597.	0.6	12
142	Inversion 3 Cytogenetic Abnormality in an Allogeneic Hematopoietic Cell Transplant Recipient Representative of a Donor-Derived Constitutional Abnormality. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1582-1587.	2.0	3
143	Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. <i>Blood Cancer Journal</i> , 2017, 7, e550-e550.	2.8	21
144	Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set. <i>Blood Cancer Journal</i> , 2017, 7, e592-e592.	2.8	66

#	ARTICLE	IF	CITATIONS
145	Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 6254-6266.	3.2	26
146	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. <i>American Journal of Hematology</i> , 2017, 92, E626-E627.	2.0	3
147	Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. <i>Leukemia and Lymphoma</i> , 2017, 58, 872-881.	0.6	29
148	Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells. <i>Leukemia</i> , 2017, 31, 1434-1442.	3.3	67
149	Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. <i>Blood Cancer Journal</i> , 2017, 7, e607-e607.	2.8	52
150	Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine. <i>Oncotarget</i> , 2017, 8, 94569-94579.	0.8	4
151	Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison. <i>International Journal of Cancer</i> , 2016, 138, 1545-1553.	2.3	14
152	Vancomycin-resistant <i>Enterococcus</i> colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. <i>Transplant Infectious Disease</i> , 2016, 18, 913-920.	0.7	40
153	Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. <i>Leukemia Research</i> , 2016, 50, 112-115.	0.4	8
154	Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. <i>Blood Cancer Journal</i> , 2016, 6, e414-e414.	2.8	23
155	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1431-1439.	2.0	26
156	Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. <i>International Journal of Hematology</i> , 2016, 103, 409-415.	0.7	0
157	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS mutant relapsed or refractory myeloid malignancies. <i>Cancer</i> , 2016, 122, 1871-1879.	2.0	113
158	ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning. <i>Transfusion</i> , 2016, 56, 518-527.	0.8	14
159	Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1714-1715.	0.6	7
160	Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. <i>Blood Cancer Journal</i> , 2016, 6, e405-e405.	2.8	30
161	Effect of the type of treatment facility on the outcome of acute myeloid leukemia in adolescents and young adults. <i>Leukemia</i> , 2016, 30, 1177-1180.	3.3	9
162	Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease. <i>Blood</i> , 2016, 128, 2799-2799.	0.6	5

#	ARTICLE	IF	CITATIONS
163	Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age ≥60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial. <i>Blood</i> , 2016, 128, 339-339.	0.6	7
164	Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis. <i>Oncotarget</i> , 2016, 7, 36382-36394.	0.8	14
165	Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 1996-1996.	0.6	0
166	Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2016, 128, 110-110.	0.6	4
167	The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 114.	6.9	48
168	Monosomal Karyotype Predicts Adverse Prognosis in Patients Diagnosed With Chronic Myelomonocytic Leukemia: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e39-e41.	0.2	6
169	Leukemic Polyradiculopathy Due to Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>JAMA Neurology</i> , 2015, 72, 938.	4.5	2
170	Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. <i>Leukemia</i> , 2015, 29, 741-744.	3.3	38
171	Primary Myelodysplastic Syndromes. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1623-1638.	1.4	16
172	Momelotinib treatment-associated emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. <i>British Journal of Haematology</i> , 2015, 169, 77-80.	1.2	56
173	Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 546-549.	0.2	20
174	Prognostic impact of combined NPM1+/FLT3 ^{ITD} genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. <i>Leukemia Research</i> , 2015, 39, 1207-1213.	0.4	7
175	Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. <i>Leukemia</i> , 2015, 29, 498-500.	3.3	20
176	Comparative Analysis of Azacitidine and Decitabine in Myelodysplastic Syndromes: A Systematic Review and Network Meta-Analysis. <i>Blood</i> , 2015, 126, 1692-1692.	0.6	2
177	Patients with Therapy-Related Myelodysplastic Syndromes (t-MDS) Have Shorter Median Overall Survival Than De Novo MDS: Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 5234-5234.	0.6	3
178	Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis. <i>Blood</i> , 2015, 126, 55-55.	0.6	3
179	A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TA signa) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Interim Results. <i>Blood</i> , 2015, 126, 3808-3808.	0.6	0
180	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. <i>Blood</i> , 2015, 126, 3730-3730.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Impact of the Type of Treatment Facility on the Outcome of Acute Myeloid Leukemia in the Adolescents and Young Adults: A National Cancer Data Base (NCDB) Study from 2003-2011. <i>Blood</i> , 2015, 126, 529-529.	0.6	0
182	Response to Hypomethylating Agents in Myelodysplastic Syndromes Based on WHO 2008 Subtypes and IPSS-R Stratification and Impact on Survival. <i>Blood</i> , 2015, 126, 5260-5260.	0.6	0
183	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. <i>Blood</i> , 2015, 126, 4062-4062.	0.6	0
184	Myelodysplastic Syndromes and Acute Myelogenous Leukemia Resulting from Therapy for Autoimmune Disease, a Case-Control Cohort Study. <i>Blood</i> , 2015, 126, 5636-5636.	0.6	0
185	Clinical Characteristics and Outcome of Adult Acute Erythroleukemia; Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4980-4980.	0.6	0
186	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. <i>Blood</i> , 2015, 126, 2490-2490.	0.6	0
187	Clofarabine Based Chemotherapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma-a Single Institution Experience. <i>Blood</i> , 2015, 126, 4910-4910.	0.6	0
188	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. <i>Blood</i> , 2015, 126, 2875-2875.	0.6	0
189	Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis. <i>Blood</i> , 2015, 126, 1401-1401.	0.6	0
190	Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1913-1913.	0.6	0
191	Disparity in the Overall Survival Improvement over Time and the Effect Time-to-Treatment on the Outcome of Acute Promyelocytic Leukemia: A US National Cancer Data Base Study from 1998-2011. <i>Blood</i> , 2015, 126, 3747-3747.	0.6	0
192	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. <i>Blood</i> , 2015, 126, 4993-4993.	0.6	0
193	Clinical Outcome of Hypomethylating Agents in Hypocellular MDS: Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 5254-5254.	0.6	0
194	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. <i>Blood</i> , 2015, 126, 4370-4370.	0.6	0
195	A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis. <i>Oncotarget</i> , 2014, 5, 5494-5509.	0.8	47
196	Clinical Outcome of Patients Diagnosed with Myelodysplastic Syndrome-Unclassifiable (MDS-U): Single Center Experience. <i>Blood</i> , 2014, 124, 3264-3264.	0.6	1
197	Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2013, 3, e122-e122.	2.8	14
198	Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. <i>Leukemia</i> , 2013, 27, 1504-1510.	3.3	190

#	ARTICLE	IF	CITATIONS
199	Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. <i>Leukemia</i> , 2013, 27, 1322-1327.	3.3	212
200	Prognostic impact of <i>RAS</i> mutations in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 365-369.	2.0	30
201	Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses. <i>Blood</i> , 2013, 122, 2745-2745.	0.6	5
202	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. <i>Blood</i> , 2013, 122, 4049-4049.	0.6	1
203	Hepatic and Metabolic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. <i>Blood</i> , 2013, 122, 1405-1405.	0.6	0
204	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. <i>Blood</i> , 2013, 122, 4048-4048.	0.6	0
205	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. <i>Blood</i> , 2013, 122, 4955-4955.	0.6	0
206	A Novel Prognostic Model To Predict Relapse After Allogeneic Stem Cell Transplantation For Myelodysplastic Syndromes. <i>Blood</i> , 2013, 122, 2098-2098.	0.6	0
207	Correlation Of Outcomes Of Allogeneic Stem Cell Transplants For Chronic Myelomonocytic Leukemia With The Mayo Prognostic Model. <i>Blood</i> , 2013, 122, 5226-5226.	0.6	0
208	Thromboembolic and Hemorrhagic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. <i>Blood</i> , 2013, 122, 3873-3873.	0.6	1
209	Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2013, 122, 1334-1334.	0.6	1
210	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. <i>Blood</i> , 2013, 122, 5000-5000.	0.6	0
211	Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients. <i>Haematologica</i> , 2012, 97, 235-240.	1.7	14
212	Autoimmunity in Patients (pts) with Chronic Myelomonocytic Leukemia (CMML): A Frequent Finding. <i>Blood</i> , 2012, 120, 4930-4930.	0.6	3
213	Treatment-Related AML Patients Previously Treated with Taxanes for Breast Cancer Have Similar Outcomes As De Novo AML. <i>Blood</i> , 2012, 120, 3555-3555.	0.6	6
214	FLT3 Mutation Predicts Worse Clinical Outcome of Relapsed Acute Myeloid Leukemia (rAML) Patients (Pts): Mayo Clinic Experience.. <i>Blood</i> , 2012, 120, 2525-2525.	0.6	0
215	Loss of the Y Chromosome Predicts Lower Complete Cytogenetic Remission Rate in Patients (pts) with Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2012, 120, 4804-4804.	0.6	0
216	Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 1476-1476.	0.6	1

#	ARTICLE	IF	CITATIONS
217	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. Blood, 2011, 118, 460-460.	0.6	2
218	IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,. Blood, 2011, 118, 3795-3795.	0.6	0
219	Transferrin Saturation (TS) Is a Surrogate Marker for Iron Deficiency Anemia (IDA),. Blood, 2011, 118, 3175-3175.	0.6	0